Physical Activity, Sedentary Behaviour and Cardiometabolic Health in Multiple Sclerosis
NCT ID: NCT05752630
Last Updated: 2023-03-02
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
50 participants
OBSERVATIONAL
2023-01-30
2024-01-20
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Sit Less or Exercise More: Impact on Cardiometabolic Health in MS
NCT03919058
Physical Activity Intervention for Improving Vascular Comorbidity Risk in Multiple Sclerosis
NCT03944538
Physiotherapist-guided Home Exercise in Moderate to Severe MS
NCT03039400
Reducing Sedentary Behaviour: A Novel Opportunity for Managing Comorbidity in MS?
NCT03136744
Promoting Physical Activity Behavior in Persons With Multiple Sclerosis
NCT01572207
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
In most studies PwMS and HC were matched on age, sex, height and weight. Importantly, differences in physical activity (PA) and sedentary behaviour (SB) were never taken into account, while this might be a relevant matching risk factor between groups. Moreover, Ranadive et al. found a significant worse vascular function in PwMS compared to HC, but differences were accounted for by low PA in PwMS. This might mean that PwMS can completely attenuate their increased CM risk by increasing their PA. However, this conclusion was only based on a statistical correction, there was a large difference in PA between groups and other confounding factors (such as PA intensity, smoking and nutrition intake) were not taken into account.
Therefore, the present study aims to investigate the relation between CM health and different intensities of PA and SB in PA-matched PwMS and HC. When CM health is comparable between PwMS and HC with similar PA levels, this shows the importance of including PA and SB measures and interventions as early as possible in MS treatment before automatically starting CM medication because PwMS are known to have multiple risk factors.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
CROSS_SECTIONAL
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Healthy control
Healthy controls who engage in sedentary behaviour for more than 9 hours per day. Strata will be used to ensure equal distribution of active and inactive participants (\< and \> 150min/MVPA/week)
No interventions assigned to this group
Persons with MS
Persons suffering from MS who engage in sedentary behaviour for more than 9 hours per day. Strata will be used to ensure equal distribution of active and inactive participants (\< and \> 150min/MVPA/week)
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* 25-60 years old
* EDSS \< 5
* Sedentary behaviour (\>9hours daily)
Exclusion Criteria
* experienced an acute exacerbation within 6 months before the start of the study
* an expanded disability status scale (EDSS) score \>5
* experimental drug use or medication changes in the last month
* medical conditions precluding PA participation
* alcohol abuse (\>20 units/week)
* reported dietary habits or weight loss (\>2kg) in the last month before the study
* intention to start a new specific diet or start to follow an exercise intervention
* reported participation in another biomedical trial which may have an effect on blood parameters 1 month before the start of the study
* blood donation in the past month
* diagnosis of cardiometabolic diseases such as diabetes mellitus or heart and vascular diseases.
25 Years
60 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Hasselt University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Bert Op't Eijnde
Principal Investigator
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Bert Op 't Eijnde, prof.dr.
Role: STUDY_CHAIR
Hasselt University
Ine Nieste, drs.
Role: PRINCIPAL_INVESTIGATOR
Hasselt University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Hasselt University
Diepenbeek, Limburg, Belgium
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CAMS
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.